All News

A recent study explored cannabis use and age-related cognitive decline in men, taking into account first use of cannabis and usage frequency.

A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.

This month’s webinar covered recent studies on cannabis use during pregnancy, CBD and anxiety, cannabis tea, and more.

The hemp products were seized from the ABC licensed locations for being out compliance with the state's new regulations.

Several surveys from 2024 reveal data and characteristics of adult American cannabis usage and opinions.

On November 5, 2024, Floridians will decide on Amendment 3, which proposes legalizing recreational cannabis. Former President Trump has stated support for this measure, aligning with his stance on state-level cannabis policies.

Aspergillus, a genus of mold that is abundant in our environment, has become a significant concern in the cannabis industry, particularly due to the health risks it poses to consumers. This mold, which thrives in various environments, including soil, decaying vegetation, and even in the air, is not inherently dangerous to healthy individuals. However, its presence in cannabis flowers, whether during cultivation, processing, or storage, can lead to severe health risks, especially for immunocompromised individuals.

Here, Scott Mazza, Founder of Vitality CBD, discusses applying cannabidiol (CBD) in pets.

This month’s webinar covered research on cannabis studied as a treatment for rheumatic disorders, menstrual symptoms, eczema, and more.

The new hemp regulations, limiting THC levels in products, took effect in September.

The new Peak PRO line by Superior LED Technologies increases performance by 12% while saving energy.

MM411’s president and co-founder, Chris DeVol, discusses challenges and trends in global cannabis education, plus upcoming initiatives of the company.

The US Hemp Authority announced that they are starting the country’s first Adult Hemp Product certification program.

Vice President Kamala Harris unveiled her cannabis legalization plan as part of her 2024 presidential campaign.

Several cannabis products in Maine were recalled due to concerns of mold and bacteria exposure.

RXDco has manufactured a new cannabis packaging option called Cocoon Jars.

Researchers shared their latest research on the fungus that is a threat to seeds and crops across the nation.

This report is the first one published since the state’s legal market began.

Overall, the survey revealed that people with chronic pain supported policies expanding medical cannabis access more than physicians.

The studies highlight how changes in environment can alter cannabis during drying and curing.

In preparation for the outdoor cannabis harvest, this episode provided guidance on ensuring a successful production process.

Researchers analyzed studies from the past two decades on the impact of cannabinoids on neuropathic pain and potential benefits.

Multi-state cannabis company, Verano Holdings Corp., started a fundraising campaign with their BITS™ edibles product for Breast Cancer Awareness Month with a portion of the proceeds going to the Lynn Sage Breast Cancer Foundation.

The study surveyed cannabis patients across the country on their use and perceptions of cannabis use during cancer treatment.

Avicanna released information on a new study through MyMedi.ca which will look into the use of medical cannabis for various health ailments such as pain, anxiety, epilepsy, sleep, and depression.

A ruling is expected this week regarding the lawsuit challenging the validity of signatures collected for two medical cannabis measures.

Panelists discussed the impacts of cannabis as a schedule 3 substance on research, legislation, patients, and more.

The study found improvement in symptom relief with participants who used the suppositories, compared to the treatment-as-usual group.

A "Secret Shopper" investigation conducted by Our Delaware and the National Clinical Directors Consortium revealed alarming compliance issues in Delaware's cannabis industry. The study discovered instances of mislabeling, product contamination, and the presence of synthetic cannabinoids in cannabis products. The findings highlighted the necessity for better regulation, accurate labeling, and public health protection.

Several participants reported symptom relief and reduced reliance on pain medication.